Veredus Laboratories Confirms VereFlu(TM) Lab-on-Chip Detects the Current Subtype of Avian Flu H7N9 in Addition to All Other Human Flu Subtypes
(Thomson Reuters ONE) -
VereFlu(TM) is based on STMicroelectronics' industry-proven Lab-on-Chip platform
Singapore, April 10, 2013 - Veredus Laboratories today announced that the
current version of VereFlu detects the current subtype of H7N9 (Avian Flu) that
is responsible for the Flu outbreak in China. H7N9 is the latest mutation to
cause concern and increased surveillance in the region. Launched in 2008 and
built on the STMicroelectronics lab-on-chip platform, VereFlu run on Veredus'
VerePLEX(TM) biosystem is the market's first test to integrate two powerful
molecular biological applications, Polymerase Chain Reaction (PCR) and a
microarray, onto a Lab-on-Chip platform.
VereFlu is a portable lab-on-chip application for rapid detection of all major
influenza types at the point of need. Unlike existing diagnostic methods,
VereFlu is a breakthrough molecular diagnostic test that can detect infection
with high accuracy and sensitivity, within two hours, providing genetic
information on the infection that traditionally could take days to weeks to
learn. With its high level of automation, users outside the traditional lab
environment can easily perform the tests at the point of need. In addition to
the current H7N9 Avian Flu, VereFlu is proven to identify and differentiate
human subtypes of Influenza A (H1, H3, H5, H7, H9) and B viruses, including the
Avian Flu subtype H5N1, and the 2009 pandemic H1N1/2009, all in a single test.
"After learning of the outbreak in China, we have confirmed in-silico[1] that
our current VereFlu influenza panel is able to detect the subtype of H7N9
responsible for this outbreak in addition to other human Flu A and B
infections," said Rosemary Tan, chief executive officer of Veredus. "This
confirms our vision when we designed the panel for the need to have a
multiplexed molecular test to detect not only the typical seasonal influenza
subtypes but also novel emerging subtypes, including the current H7N9 subtype,
capable of making the jump from animals to humans. Our customers can be assured
that with VereFlu they are able to detect H7N9 and we are able to deliver
immediately a fast, reliable surveillance system that can be deployed to help
monitor the current situation."
About Veredus Laboratories Pte Ltd
Veredus Laboratories Pte Ltd was founded in 2003 and launched its first products
in 2005. Veredus is a Singapore-based majority-owned subsidiary of
STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers
across the spectrum of electronics applications.
Veredus specializes in the development, manufacture, and marketing of innovative
multiplexed molecular solutions in the clinical, specialty, and custom testing
markets based on STMicroelectronics' proprietary Lab-on-Chip platform. The Lab-
on-Chip platform, marketed as the VerePLEX(TM) biosystem, combines Micro-
Electro-Mechanical-Systems (MEMS) with micro-fluidics to integrate multiplexed
DNA amplification with microarray detection for rapid, cost-effective, and
accurate analysis of biological materials.
About STMicroelectronics
ST is a global leader in the semiconductor market serving customers across the
spectrum of sense and power and automotive products and embedded processing
solutions. From energy management and savings to trust and data security, from
healthcare and wellness to smart consumer devices, in the home, car and office,
at work and at play, ST is found everywhere microelectronics make a positive and
innovative contribution to people's life. By getting more from technology to get
more from life, ST stands for life.augmented.
In 2012, the Company's net revenues were $8.49 billion. Further information on
ST can be found at www.st.com.
VereFlu and VerePLEX are trademarks of Veredus Laboratories.
For further information, please contact:
Boey Taik Boon
Corporate External Communications
STMicroelectronics Asia-Pacific
Tel: +65 6427 7765
Email: taik-boon.boey(at)st.com
Hazelle Lam
Director, Sales and Marketing
Veredus Laboratories Pte Ltd
Mobile: +65 9431 3790
Email: hazelle.lam(at)vereduslabs.com
Tony Barbuzzi
Business Development Manager
STMicroelectronics, SRL
Mobile : +393400872836
Email : tony.barbuzzi(at)st.com
--------------------------------------------------------------------------------
[1] in simulations based on known DNA sequences of H7N9
VereFlu Lab on Chip:
http://hugin.info/152740/R/1691826/555686.pdf
VereFlu Lab on Chip_IMAGE:
http://hugin.info/152740/R/1691826/555688.jpg
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: STMicroelectronics via Thomson Reuters ONE
[HUG#1691826]
Unternehmensinformation / Kurzprofil:
Datum: 10.04.2013 - 09:00 Uhr
Sprache: Deutsch
News-ID 247587
Anzahl Zeichen: 5655
contact information:
Town:
Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 178 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Veredus Laboratories Confirms VereFlu(TM) Lab-on-Chip Detects the Current Subtype of Avian Flu H7N9 in Addition to All Other Human Flu Subtypes"
steht unter der journalistisch-redaktionellen Verantwortung von
STMicroelectronics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
